PT  - JOURNAL ARTICLE
AU  - Gihan P. Ruwanpathirana
AU  - Robert C. Williams
AU  - Colin L. Masters
AU  - Christopher C. Rowe
AU  - Leigh A. Johnston
AU  - Catherine E. Davey
TI  - Impact of PET reconstruction on Aβ-amyloid quantitation in cross-sectional and longitudinal analyses
AID  - 10.1101/2023.07.03.23292155
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.03.23292155
4099  - http://medrxiv.org/content/early/2023/07/03/2023.07.03.23292155.short
4100  - http://medrxiv.org/content/early/2023/07/03/2023.07.03.23292155.full
AB  - Amyloid beta (Aβ) accumulation in Alzheimer’s disease (AD) is typically measured using standardized uptake value ratio (SUVR) and the Centiloid scale (CL). The low spatial resolution of PET images is known to degrade quantitative metrics due to the partial volume effect (PVE). This paper examines the impact of spatial resolution, as determined by the reconstruction configuration, on the Aβ-PET quantitation in both cross-sectional and longitudinal data.Methods Cross-sectional Study-89 subjects with [18F]-florbetapir scans (44 Aβ-, 45 Aβ+) were reconstructed using 69 reconstruction configurations. For each reconstruction, Aβ SUVR was calculated and the spatial resolution was calculated as full-width-at-half-maximum (FWHM) using the barrel phantom method (Lodge et al, 2018). The change of SUVR and the effect size of the difference in SUVR between Aβ- and Aβ+ groups with FWHM were examined.Longitudinal study-79 subjects (46 Aβ-, 33 Aβ+) with three [18F]-flutemetamol scans were analysed. All scans were reconstructed using low-, medium- and high-resolution reconstruction configurations and Aβ CLs were calculated. Since linear Aβ accumulation was assumed over a 10-year interval, for each reconstruction configuration, Aβ accumulation rate differences (ARD) between the second and first periods were calculated for all the subjects and compared. Zero ARD was used as a consistency metric. The number of Aβ-accumulators was also used to compare reconstruction configurations.Results Cross-sectional-SUVRs in both Aβ- and Aβ+ groups were impacted by the FWHM of the reconstruction method; Aβ- SUVRs increased for FWHM ≥ 4.5 mm, while Aβ+ SUVRs decreased across the FWHM range. High-resolution reconstructions provided the best statistical separation between groups.Longitudinal study-In the Aβ-group, the median ARD of low-resolution reconstructed data was greater than zero whereas the ARDs of higher-resolution reconstructions were not significantly different to zero, indicating less consistent rates in the low-than the higher-resolution data. Higher-resolution reconstructions identified 10 additional Aβ-accumulators in the Aβ-group, resulting in a 22% increased group size compared to the low-resolution reconstructions. Higher-resolution reconstructions reduced the average CL values of the negative group by 12 points.Conclusions High-resolution PET reconstructions, inherently less impacted by PVE, may improve Aβ-PET quantitation in both cross-sectional and longitudinal data. In the cross-sectional analysis, separation of Aβ groups’ SUVRs increased with spatial resolution. Longitudinal analysis showed better Aβ accumulation consistency in higher-resolution compared to low-resolution reconstructions. The identification of more Aβ-accumulators from the higher-resolution reconstruction may be helpful in early-stage AD therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research was supported by NHMRC and NIH grants. No potential conflicts of interest relevant to this article exist. The first author would also like to acknowledge the Rowden White scholarship for its assistance in his research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The human scans were approved by the Austin health Human Research Ethics Committee (HREC/18/Austin/201) and all experiments were performed in accordance with relevant guidelines and regulations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the Australian Imaging and Biomarkers Lifestyle Study.